Multiple System Atrophy (MSA) Markt GRÖSSEN- UND MARKTANTEILSANALYSE - WACHSTUMSTRENDS UND PROGNOSEN (2024 - 2031)
Multiple System Atrophy (MSA) Markt wird durch Subtyp (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online) segmented. Der Bericht bietet den Wert (in USD Million) für die oben genannten Segmente. Multiple System Atrophy (MSA) Markt wird durch Subtyp (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online) segmented. Der Bericht bietet den Wert (in USD Million) für die oben genannten Segmente. wird von Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) segmentiert. Der Bericht bietet den Wert (in USD Million) für die oben genannten Segmente.
Competitive overview of Multiple System Atrophy (MSA) Market
Die wichtigsten Spieler, die im Multiple System Atrophy (MSA) Markt tätig sind, sind Merck & Co., Neuropore Therapies Inc., Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc., Stealth BioTherapeutics Corp., AFFiRiS AG, Corestem Inc., MitoDys Therapeutics Ltd., Modag GmbH, Acadia Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Eli Lilly und Company und Johnson
Multiple System Atrophy (MSA) Market Leaders
- Chelsea Therapeutics International, Ltd.
- Biohaven Pharmaceuticals, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- AstraZeneca pl
- Theravance Biopharma Inc.
Multiple System Atrophy (MSA) Market - Competitive Rivalry, 2023
Multiple System Atrophy (MSA) Market
(Dominated by major players)
(Highly competitive with lots of players.)